周三盘后，糖尿病医疗设备制造商Tandem Diabetes Care（TNDM）股价大跌18%，主要原因是公司发布的第二季度财报未能达到分析师预期。
根据公司财报，截至6月30日的第二季度，Tandem Diabetes调整后每股亏损为0.48美元，与去年同期持平，但未能达到华尔街分析师平均预期的0.40美元亏损。尽管公司季度营收同比增长8.5%至2.4068亿美元，略高于分析师预期的2.3857亿美元，但仍未能抵消盈利方面的失望。更值得注意的是，公司本季度净亏损高达5240万美元。
这份疲软的财报进一步加剧了投资者对Tandem Diabetes长期表现的担忧。数据显示，该公司股价在本季度已下跌18.7%，今年迄今为止更是暴跌57.9%。尽管分析师对公司的平均评级仍为"持有"，且12个月目标价中位数为27.00美元，较当前股价有46.7%的上涨空间，但投资者似乎对公司近期的财务表现持谨慎态度。在当前激烈的医疗设备市场竞争中，Tandem Diabetes能否扭转局面，重回增长轨道，将成为投资者密切关注的焦点。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.